Julkaisut

image_pdf

List of publications by ESiOR personnel since 2006

Tieteelliset julkaisureferenssit
Scientific publication references

Tieteelliset konferenssireferenssit
Scientific conference references

Muut julkaisut
Other publications

Tieteelliset julkaisureferenssit 2006-

Scientific publication references 2006-

 

2017

Miettola E, Koskela TH, Soini E, et al. Mikä on terveyskeskuspotilaiden elämänlaatu? Yleislääkäri 2017;32:21-6.

Soini E, et al. Cost-Utility of First-Line Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Clin Ther (2017) 10.1016/j.clinthera.2017.01.028. Open access.

Hongisto K, Hallikainen I, Selander T, Törmälehto S, Väätäinen S, Martikainen J, et al. Quality of Life in relation to neuropsychiatric symptoms in Alzheimer’s disease. Int J Geriatr Psychiatry 2017. [Epub ahead of print].

 

2016

Martikainen JA, et al. Longterm Work Productivity Costs Due to Absenteeism and Permanent Work Disability in Patients with Early Rheumatoid Arthritis: A Nationwide Register Study of 7831 Patients. J Rheumatol 2016;43:2101-5.

von Bonsdorff ME, von Bonsdorff MB, Martikainen J, et al. Body size at birth and coronary heart disease-related hospital care in adult men – findings from the Helsinki Birth Cohort Study. Ann Med 2016 Nov 3:1-8. [Epub ahead of print].

Aarnio E, Martikainen J, et al. Socioeconomic Inequalities in Statin Adherence Under Universal Coverage: Does Sex Matter? Circulation: Cardiovascular Quality and Outcomes 2016 Oct 18. pii: CIRCOUTCOMES.116.002728. [Epub ahead of print].

Soini E, Hallinen T, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Review of Pharmacoeconomics & Outcomes Research 2016. Journal page.

Hautala AJ, Kiviniemi AM, Mäkikallio T, Koistinen P, Ryynänen OP, Martikainen JA, et al. Economic evaluation of exercise-based cardiac rehabilitation in patients with a recent acute coronary syndrome. Scandinavian Journal of Medicine & Science in Sports 2016 Aug 19. doi: 10.1111/sms.12738. [Epub ahead of print].

Hallinen T, Soini E, et al. Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients. SpringerPlus 2016;5:1354. Open access.

Heiskanen J, Martikainen J, et al. The coverage of elective revascularisation procedure codes in the National Finnish Hospital Discharge Register. Annals of Medicine 2016 Aug 5:1-7. Epub ahead of print.

Soini E, Hautala A, Poikonen E, Becker U, Kyttälä M, Martikainen J. Cost-Effectiveness of First-Line Chronic Lymphocytic Leukemia Treatments When Full-Dose Fludarabine Is Unsuitable. Clin Ther 2016;38:889-904. Open access.

Väätäinen S, Cederberg H, Roine R, Keinänen-Kiukaanniemi S, Saramies J, Uusitalo H, Tuomilehto J, Martikainen J. Does Future Diabetes Risk Impair Current Quality of Life? A Cross-Sectional Study of Health-Related Quality of Life in Relation to the Finnish Diabetes Risk Score (FINDRISC). PLoS One 2016;11:e0147898. Open access.

Heiskanen J, Tolppanen A-M, Roine RP, Hartikainen J, Hippeläinen M, Miettinen H, Martikainen J. Comparison of EQ-5D and 15D instruments for assessing the health-related quality of life in cardiac surgery patients. European Heart Journal – Quality of Care and Clinical Outcomes 2016. Open access.

Koivisto AM, Hallikainen I, Välimäki T, Hongisto K, Hiltunen A, Karppi P, Sivenius J, Soininen H, Martikainen J. Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers’ well-being. Int J Geriatr Psychiatry 2016;31:273-83. Journal website.

Välimäki TH, Martikainen JA, Hongisto K, Väätäinen S, et al. Impact of Alzheimer’s disease on the family caregiver’s long-term quality of life. Qual Life Res 2016;25:687-97. Journal website.

Asklöf T, Martikainen J, et al. Paid expenditures and productivity costs associated with permanent disability pensions in patients with spinal disorders: Nationwide Finnish Register-based Study, 1990-2010. European Spine Journal 2016;25:275-81. Journal website.

 

2015

Heinonen J, Koskela T, Soini E, et al. Primary-care-based episodes of care and their costs in a three-month follow-up in Finland. Scand J Prim Health Care 2015;33:283-90. Open access.

Törmälehto SM, Martikainen JA, Väätäinen ST, et al. Use of Anti-Dementia Drugs in Relation to Change in Cognition, Behavior, and Functioning in Alzheimer’s Disease over a Three-Year Period. Journal of Alzheimer’s Disease 2015;48:1033-41. Journal website.

Välimäki TH, Martikainen JA, Hallikainen IT, Väätäinen ST, et al. Depressed Spousal Caregivers Have Psychological Stress Unrelated to the Progression of Alzheimer Disease: A 3-Year Follow-Up Report. Journal of Geriatric Psychiatry and Neurology 2015;28:272-80. Journal website.

Soini E, Hallinen T, Sokka AL, Saarinen K. Cost-Utility of First-Line Actinic Keratosis Treatments in Finland. Advances in Therapy 2015;32:455-76. Open Access.

Gilmartin JF, Väätäinen S, Törmälehto S, Bell JS, Lönnroos E, Salo L, Hallikainen I, Martikainen J, et al. Depressive symptoms are associated with analgesic use in people with Alzheimer’s disease. PLoS One 2015;10:e0117926. Open access.

Aarnio E, Korhonen MJ, Huupponen R, Martikainen J. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence – Estimates from the Finnish prescription register. Atherosclerosis 2015;239:240-7. Journal website.

 

2014

Hallikainen I, Martikainen J, et al. The Progression of Alzheimer’s Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery. Dementia and Geriatric Cognitive Disorders EXTRA 2014;4:494-508. Open access.

Kangaspunta V, Koskela T, Soini E, et al. Potilaiden arvioon terveyskeskuskäynnin hyödystä vaikuttavat tekijät. Suom Lääkäril 2014;69:51-6. PDF.

Tuomilehto H, et al. The impact of weight reduction in the prevention of the progression of obstructive sleep apnea: an explanatory analysis of a 5-year observational follow-up trial. Sleep Medicine 2014;15:329-35. Collaborators: Soini E, Martikainen J. PDF.

Martikainen J, Soini E, et al. Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults >50 years with underlying chronic medical conditions. Journal of Evaluation in Clinical Practice 2014;20:333-41. Journal website.

Välimäki T, Martikainen J, et al. Decreasing sense of coherence and its determinants in spousal caregivers of persons with mild Alzheimer’s disease in three year follow-up. International Psychogeriatrics 2014;26:1211-20. Open access.

Väätäinen S, Keinänen-Kiukaanniemi S, Saramies J, Uusitalo H, Tuomilehto J, Martikainen J. Quality of life along the diabetes continuum: a cross-sectional view of health-related quality of life and general health status in middle-aged and older Finns. Qual Life Res 2014;23:1935-44. Journal website.

Hallinen T, Soini E, et al. Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary health care data. BMJ Open 2014;4:e004071. Open access.

 

2013

Tuomilehto H, et al. Weight Reduction and Increased Physical Activity to Prevent the Progression of Obstructive Sleep Apnea: A 4-Year Observational Postintervention Follow-up of a Randomized Clinical Trial. JAMA Internal Medicine 2013;173:930-2. Collaborators: Soini E, Martikainen J. Journal website.

Aarnio E, Martikainen J, et al. Register-based predictors of adherence among new statin users in Finland. Journal of Clinical Lipidology 2014;8:117-25. Open access.

Soini E, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus 2013;2:531. Open access.

Väätäinen S, Tuomilehto H, Saramies J, Tuomilehto J, Uusitalo H, Hussi E, Keinänen-Kiukaanniemi S, Martikainen J. The health-related quality-of-life impact of nocturnal awakenings in the middle-aged and older Finnish population. Quality of Life Research 2013;22:2737-48. Journal website.

Hallikainen M, et al. Cholesterol Metabolism and Weight Reduction in Subjects with Mild Obstructive Sleep Apnoea: A Randomised, Controlled Study. Cholesterol 2013;769457. Colloborators: Soini E, Martikainen J. Open access.

Willis M, et al. Validation of Economic and Health Outcomes simulation model of Type 2 Diabetes Mellitus (ECHO-T2DM). J Med Econ 2013;16:1007-1021. Journal website.

Theidel U, et al. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany. Clinical Research in Cardiology 2013;102:447-458. Open access.

Ryynänen OP, Soini, E, et al. Bayesian predictors of very poor health related quality of life and mortality in patients with COPD. BMC Medical Informatics and Decision Making 2013;13:34. Open access.

Lehto SM, Sahlman J, Soini E, et al. The association between anxiety and the degree of illness in mild obstructive sleep apnoea. The Clinical Respiratory Journal 2013;7:197-203. Journal website.

Ryynänen OP, Nousiainen P, Soini E, et al. Efficacy of a multicomponent support programme for the caregivers of disabled persons: A randomized controlled study. Zeitschrift für Gerontologie und Geriatrie 2013;46:449-455. Journal website.

 

2012

Ramsberg J, et al. Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7:e42003. Open access.

Hallinen T, Soini E, et al. Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012;2:e000915. Open access.

Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 2012;28:382-389. Open access.

Soini E, et al. Contingent Valuation of Eight New Treatments: What is the Clinician’s and Politician’s Willingness to Pay? The Open Complementary Medicine Journal 2012;4:1-11. Open access.

Soini E, Martikainen JA, et al. Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 2012;34:915-25. Journal website.

Asseburg C, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection. Schizophrenia Research and Treatment 2012; Article 791468:1-9. Open access.

Soini E, Hallinen TA, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15:1-12. Journal website.

Manca A, et al. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value Health 2011;15:22-31. Open access.

Hallinen T, Soini E, et al. Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä. Dosis 2012;28:130-44. Journal website.

Hallinen T, Soini E, et al. Cost-effectiveness of insulin glargine compared to other long-acting basal insulins in the treatment of Finnish type 1 and type 2 diabetes patients based on individual studies. Dosis 2012;28:145-64. Journal website.

Peura PK, Martikainen JA, et al. Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review. Medical Decision Making 2012;32:237-45. Journal website.

Cummins E, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. European Journal of Health Economics 2012;13(6):801-809. Journal website.

 

2011

Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Ger Psych 2011;26:473-82. Journal website.

Hallinen T, Soini E. The impact of the pharmaceutical pricing system on cost-effectiveness results: Finnish analysis. The Open Pharmacoeconomics & Health Economics Journal 2011;3:6-10. Open access.

Soini E, Martikainen J, et al. Treatment of follicular non-Hodgkin lymphoma with or without rituximab: Cost-effectiveness and value of information based on 5-year follow-up. Ann Oncol (English Excerpted Edition, South Africa) 2011;8. Originally published in Ann Oncol 2011;22:1189-97. Open access.

Martikainen J, Soini E, et al. The health economic consequences of reducing salt and replacing intake of saturated fat with polyunsaturated fat in the adult Finnish population – Estimates based on the FINRISK and FINDIET studies. European Journal of Clinical Nutrition 2011;65:1148-55. Open access.

Soini E. Cost-utility and expected value of perfect information related to trabectedin in the treatment of metastatic soft-tissue sarcoma: the publicly funded comments explored. Ann Oncol 2011;22:1465-6. Open access.

Cummins E, et al. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. Value Health 2011;14:15-23. Open access.

Peura P, Asseburg C, Turunen J, Purmonen T, Martikainen J. Epäsuora vertailu ja verkostometa-analyysit – uudet työkalut lääkkeiden suhteellisen tehon ja vaikuttavuuden arviointiin. (Indirect comparison and network meta-analyses – new tools for the assessment of evidence on the relative efficacy of drugs.) Aikakauskirja Duodecim 2011;127:900-10. PDF.

Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Välimäki T, Martikainen J, et al. Neuropsychiatric symptoms and Quality of Life in patients with very mild and mild Alzheimer’s disease. International Journal of Geriatric Psychiatry 2011;26:473-82. Journal website.

Blomster H, et al. Impaired nasal breathing may prevent the beneficial effect of weight loss in the treatment of OSA. Rhinology 2011;49:587-92. Colloborators: Soini E, Martikainen J. Open Access.

Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncologica 2011;50:344-52. Open access.

Soini E, Martikainen J, et al. Treatment of follicular non-Hodgkin lymphoma with or without rituximab: Cost-effectiveness and value of information based on 5-year follow-up. Ann Oncol 2011;22:1189-97. Open access.

Asseburg C, et al. Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting. Clin Ther 2011;33:482-97. Journal website.

Soini E, et al. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Annals of Oncology 2011;22:215-23. Open access.

 

2010

Tuomilehto H, et al. Sustained improvement in mild obstructive sleep apnea after a diet- and physical activity-based lifestyle intervention: postinterventional follow-up. The American Journal of Clinical Nutrition 2010;92:688-96. Collaborators: Soini E, Martikainen J. Open access.

Purmonen TT, Auvinen PK, Martikainen JA. Budget impact analysis of trastuzumab in early breast cancer: a hospital district perspective. International Journal of Technology Assessment in Health Care 2010;26:163-9. Open access.

Koskela T, Ryynanen OP, Soini E. Risk factors for persistent frequent use of the primary health care services among frequent attenders: a Bayesian approach. Scandinavian Journal of Primary Health Care 2010;28:55-61. Open access.

Sahlman J, et al. The activation of the inflammatory cytokines in overweight patients with mild obstructive sleep apnoea. Journal of Sleep Research 2010;19:341-8. Collaborators: Soini E, Martikainen J. Open access.

Hallinen T, Soini E, et al. Cost-utility of different treatment strategies after the failure of tumor necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology (Oxford) 2010;49:767-77. Open access.

Smout S, et al. The functional response of a generalist predator. PLoS One 2010;5:e10761. Open access.

Martikainen J, Soini E, et al. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden. Curr Med Res Opin 2010;26:389-96. Journal website.

Soini E, Davies G, Martikainen J, et al. Population-based health-economic evaluation of the secondary prevention of coronary heart disease in Finland. Curr Med Res Opin 2010;26:25-36. Journal website.

Laine J, Soini E, Martikainen J. Taloudellisen arvioinnin asema terveydenhuollon menetelmien käyttöönotossa. Esimerkkinä kansallinen rokotusohjelma. Suom Lääkäril 2010;65:1019-24. Journal website.

Laine J, Soini E, Martikainen J. Toiveena taloudellisen arvioinnin lisääntyvä hyödyntäminen. Suom Lääkäril 2010;65(11):1025-6. Journal website.

Hjalte F, et al. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden – with model applications for Denmark, Norway and Finland. Journal of the European Academy of Dermatology and Venereology 2010;24:474-80. Journal website.

Wailoo AJ, et al. Primary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty Project. Heart 2010;96:668-72. Journal website.

Martikainen J, Nyblin K. Millainen on hyvä lääkkeen hoidollisen ja taloudellisen arvon arviointi? Dosis 2010;26:33-42. Journal website.

 

2009

Soini E, et al. Predicting forensic admission among the mentally ill in a multinational setting: A Bayesian modelling approach. Data & Knowledge Engineering 2009;68:1427-40. Journal website.

Kalavainen M, Karjalainen S, Martikainen J, et al. Cost-effectiveness of routine and group programs for treatment of obese children. Pediatrics International 2009;51:606-11. Journal website.

Hallinen T, Soini E, Martikainen J, et al. Costs and quality of life effects of the first year of renal replacement therapy in one Finnish treatment centre. Journal of Medical Economics 2009;12:136-40. Journal website.

Tuomilehto HPI, Seppä JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JOI, Vanninen EJ, Kokkarinen J, Sahlman JK, Martikainen T, Soini EJ, et al. Lifestyle Intervention with Weight Reduction – First Line Treatment in Mild Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine 2009;179:320-7. Open access.

Hartikainen S, Lavikainen P, Raunio H, Ahonen J, Peura P, Martikainen J, et al. Mahahaavalääkitys pienemmin kustannuksin. Finnish Medical Journal 2009;64:296-9. Journal issue website.

Martikainen J, Nyblin K. Millainen on hyvä lääkkeen hoidollisen ja taloudellisen arvon arviointi? Dosis 2009;25:209-19. Journal website.

 

2008

Tamminen K, Laine J, Soini E, Martikainen J, et al. Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland. Curr Med Res Opin 2008;24:3453-61. Journal website.

Ryynänen OP, Soini E, et al. Predicting treatment effectiveness in spinal pain – Application of a Bayesian Predicting Model. In: Lindgren K-A (ed): 8th Psychiatric Summer School. L B P, Controversies in Clinical Practice and Research 27.6.-29.6.2007. Rehabilitation ORTON Invalid Foundation, Vammalan kirjapaino, Vammala 2008. Publisher website.

Purmonen T*, Martikainen J*, Soini E, et al. Economic Evaluation of Sunitinib Malate in Second-Line Treatment of Metastatic Renal Cell Carcinoma in Finland. Clinical Therapeutics 2008;30:382-92. Journal website. *Equal contribution.

Soini E, et al. Predicting forensic admission among the mentally ill: A Bayesian approach. Proceedings of the 21st The Institute of Electrical and Electronics Engineers (IEEE) International Symposium on Computer-Based Medical Systems 17-19.6.2008, Jyväskylä, Finland, p. 242-247. Eds. Puuronen S, Pechenizkiy M, Tsymbal A, Lee D-J, IEEE Computer Society, Los Alamitos, California 2008. Journal website.

Peura P, Martikainen J, Soini E, Hallinen T, et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. Curr Med Res Opin 2008:24;1825-34. Journal website.

Peura P, Purmonen T, Turunen J, Martikainen J. Voiko ulkomaisia lääkkeiden kustannusvaikuttavuusanalyysejä hyödyntää Suomessa? Suom Lääkäril 2008;63:3116-7. Journal website.

Martikainen J. Päätösanalyyttisten mallien soveltaminen terveystaloudellisessa arviointitutkimuksessa. Dosis 2008;24:268-75. Journal website.

2007

Keränen J*, Soini E*, et al. Economic evaluation comparing From Home To Operation same day admission and preoperative admission one day prior to surgery process: a randomised, controlled trial of laparoscopic cholecystectomy. Curr Med Res Opin 2007;23:2775-84. Journal website. *Equal contribution.

Ottelin A-M, Lindström J, Peltonen M, Martikainen J, et al. Costs of a self-selected, health-promoting diet among the participants of the Finnish Diabetes Prevention Study. Diabetes Care 2007:30:1275-7. Open access.

Martikainen J, et al. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach. The European Journal of Cardiovascular Prevention & Rehabilitation 2007:14:265-72. Journal website.

Laine J, Martikainen J. Lääkkeiden kustannusvaikuttavuuden arviointi Suomessa ja Ruotsissa – Näkökulmia ja kehitysehdotuksia. Dosis 2007;23:266-74. Journal website.

Peura P, Martikainen J, Hallinen T, Soini E, et al. Statiinien teho ja kustannusvaikuttavuus. Suomen Lääkärilehti 2007;62:3899-905. Journal website.

 

2006

Soini E. Incremental or average cost-utility of routine cataract surgery? Health and Quality of Life Outcomes 2006 oct 24;4:74. Open access.

Hallinen T, Martikainen J, Soini E, et al. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting. Current Medical Research and Opinion 2006;22:683-92. Journal website.

Martikainen J, Hallinen T, Soini E. Lääkkeiden taloudellinen arviointi – Lääketaloustieteen teoria, tutkimus ja käytäntö. Pharmacoeconomic Evaluation – Theory, Research and Practice. Dosis farmaseuttinen aikakauskirja 2006;22:289-300. Author copy available.

 


Tieteelliset konferenssireferenssit 2006-

Scientific conference references 2006-

 

2016

Soini E, et al. Watch out for Berkson’s Bias (BB)! Setting Health-Related Quality of Life (HRQoL) treatment targets with Matching-Adjusted Indirect Comparison (MAIC) in order to predict Matched General Population Control (MGPC) targets, assess Potential to Benefit (PtB) and reveal Unmet Medical Need (UMN). Value Health 2016 [accepted].

Soini E, et al. Health-Related Quality of Life (HRQoL) based on preferences from 14 countries in Primary Health Care Setting (PHCS). Value Health 2016 [accepted].

Soini E, et al. ICPC-2 episode-based health-related quality of life and three months effectiveness in three Finnish primary health care settings. Value Health 2016 [accepted].

Soini E, et al. Comorbidity-based EQ-5D scores of primary care patients in Finland, their potential to benefit and unmet medical need. Value Health 2016 [accepted].

Murtonen A, Holmberg M, Soini E, et al. Disease Modifying Treatment (DMT) is associated with lower hazard for death among Multiple Sclerosis (MS) patients: Survival analysis based on 30 years incident MS cohort. Value Health 2016 [accepted].

Theidel U, Väätäinen S, Martikainen J, Soini E, et al. Budget impact of iv iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. Heart Failure 2016 – Featuring the 3rd World Congress on Acute Heart Failure, European Society of Cardiology (ESC), 21-24 May 2016, Florence – Italy, P2203. Congress sessions.

Martikainen J, et al. Monitoring hospital readmissions after percutaneous coronary interventions using risk-adjusted control charts – Comparing static and dynamic rolling risk-adjustment methods. In Nykänen I (ed) 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare. Program and Abstracts p. 95-96. Kuopio, Finland, May 18-20, 2016. NSQH2016, Podium. Publications of the University of Eastern Finland Reports and Studies in Health Sciences 21. Abstract ebook.

Soini E, et al. Quality of Life, Potential to Benefit and Concordance Based on Preferences from 14 Countries. In Nykänen I (ed) 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare. Program and Abstracts p. 70. Kuopio, Finland, May 18-20, 2016. NSQH2016, Podium. Publications of the University of Eastern Finland Reports and Studies in Health Sciences 21. Abstract ebook.

Soini E, et al. Setting Quality of Life Benchmarks with Matching-Adjusted Indirect Comparison and ICPC-2 Codes: Berkson’s Bias Beware. In Nykänen I (ed) 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare. Program and Abstracts p. 68. Kuopio, Finland, May 18-20, 2016. NSQH2016. Publications of the University of Eastern Finland Reports and Studies in Health Sciences 21. Abstract ebook.

Heiskanen J, Hartikainen J, Hippeläinen M, Miettinen H, Roine RP, Martikainen J, et al. Which is more safe and effective – coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)? In Nykänen I (ed) 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare. Program and Abstracts p. 42. Kuopio, Finland, May 18-20, 2016. NSQH2016. Publications of the University of Eastern Finland Reports and Studies in Health Sciences 21. Abstract ebook.

Heiskanen J, Tolppanen AM, Hartikainen J, Hippeläinen M, Miettinen H, Martikainen J, et al. Can we improve identification of adverse events by focusing on patients with poor patient-reported outcomes? In Nykänen I (ed) 4th Nordic Conference on Research in Patient Safety and Quality in Healthcare. Program and Abstracts p. 41. Kuopio, Finland, May 18-20, 2016. NSQH2016. Publications of the University of Eastern Finland Reports and Studies in Health Sciences 21. Abstract ebook.

Martikainen J, Törmälehto S, Väätäinen S. Alzheimerin taudin terveystaloudelliset vaikutukset ja niihin yhteydessä olevat tekijät. In: Terveystaloustiede 2016, p. 10-12. Ed. Mäklin S. THL: Helsinki, 2016. Website.
Väätäinen S, Hongisto K, Välimäki T, Hallikainen I, Koivisto A, Martikainen J. Alzheimerin tautia sairastavan potilaan ja tämän omaishoitajan elämänlaatu suhteessa sairauden vaikeusasteeseen ja potilaan avuntarpeeseen. In: Terveystaloustiede 2016, p. 13-15. Ed. Mäklin S. THL: Helsinki, 2016. Website.

Törmälehto S, Bell S, Väätäinen S, Hallikainen I, Koivisto A, Martikainen J. Alzheimerin taudin lääkehoito, sen muutokset ja kustannukset pitkäaikaisseurannassa: yhteys kognitiiviseen suoriutumiseen, toimintakykyyn ja käytösoireisiin. In: Terveystaloustiede 2016, p. 16-19. Ed. Mäklin S. THL: Helsinki, 2016. Website.

 

2015

Soini E, et al. Cost-effectiveness of First-line disease-modifying treatments for relapsing-remitting MS. ECTRIMS 2015 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. P660. Abstract.

Rantalaiho V, Leirisalo-Repo M, Kautiainen H, Mankinen P, Martikainen J, et al. Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy [abstract]. Arthritis & Rheumatology 2015; 67 (suppl 10). Abstract.

Soini E, et al. Cost-effectiveness of first-line disease-modifying therapies (DMTs) for relapsing-remitting MS (RRMS). Value Health 2015;18:A756. Abstract.

Sopina E, Martikainen J, et al. Validation of a Markov model for economic evaluation of screening and preventive interventions in Alzheimer’s disease in Denmark. Value Health 2015;18:A695. Abstract.

Väätäinen S, Soini E, et al. Cost-effectiveness of ustekinumab in the treatment of psoriasis in Finland. Value Health 2015;18:A670. Abstract.

Mankinen P, Soini E, Laine J, Linna M, Åhman H, Martikainen J. Health economic impact of 13-valent pneumococcal conjugate vaccine in Finnish home care customers >50 years with underlying chronic medical conditions. Value Health 2015;18:A579. Abstract.

 

2014

Väätäinen S & Martikainen J. Disutility associated with erectile dysfunction in the middle-aged or older males. Value Health 2014;17:A514. Abstract.

Soini E, Hallinen T, et al. Cost-utility of vortioxetine in the treatment of major depressive disorder: Comparison with agomelatine, bupropion, sertraline and venlafaxine in the Finnish Setting. Value Health 2014;17:A459. Abstract.

Soini E, et al. Modelling the persistence of Disease-Modifying drug Treatment (DMT) and its independent drivers in Finnish Multiple Sclerosis (MS) patients: Parametric survival modelling. Value Health 2014;17:A400. Abstract.

Soini E, et al. Cost-Utility Analysis (CUA) of first-line Disease-Modifying Treatments (DMT) versus Best Supportive Care (BSC) in Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) patients. Value Health 2014;17:A399. Abstract.

Heinonen J, Soini E, et al. Episodes of care and their costs based on ICPC-2 classification: Three month follow-up study in Finland. Value Health 2014;17:A549. Abstract.

Soini E, Hallinen T, et al. Cost-Utility Analysis (CUA) of first-line Actinic Keratosis (AK) treatments in Finland. Value Health 2014;17:A609. Abstract.

Asseburg C. Current Challenges in the Health-Economic Modelling of Diabetes. Diabetes simulation models as prognostic tools. Medical University Vienna, Austria, September 15, 2014. Podium.

Asseburg C. Uncertainty in the Challenge 3. Mt Hood 7 Meeting on the Health-Economic Modelling of Diabetes. Stanford University, Palo Alto, CA, USA, June 18, 2014. Podium.

Soini E, et al. International normalized ratio (INR) monitoring and percent time in therapeutic INR range (TTR) can have impact on patient’s quality of life? Application of Beta regressions in a prospective 3 months setting. 15th Biennial SMDM European Meeting, Antwerpen. Program and abstracts 2014.

Soini E, et al. Glycosylated haemoglobin (HbA1c) monitoring and lower HBA1c values can result to higher quality of life? Beta regression modelling. 15th Biennial SMDM European Meeting, Antwerpen. Program and abstracts 2014.

Heinonen J, Soini E, et al. Costs of episodes (COE): analysis based on ICPC-2 classification. 15th Biennial SMDM European Meeting, Antwerpen. Program and abstracts, 2014.
Asseburg, C. Det internationella Mount Hood-samarbetet. Tredje nationella hälsoekonomiska konferensen, Lund, Sweden, 20-21 March 2014. Meeting Website.

Heinonen J, Koskela T, Soini E, et al. Terveyskeskuspotilaiden hoitoepisodit ja niiden kustannukset. Tampereen Lääkäripäivät XXXV, 19.-21.3.2014.

 

2013

Martikainen J, Kautiainen H, Väätäinen S, et al. Effectiveness of the early psychosocial intervention on institutionalization of patients with mild Alzheimer’s disease and caregivers’ quality of life. Value Health 2013;16:A618-9. Abstract.

Väätäinen S, Hongisto K, Hallikainen I, Välimäki T, Martikainen J, et al. Wellbeing, life satisfaction and progression in Alzheimer’s disease. Value Health 2013;16:A267. Abstract.

Soini E, et al. International Normalized Ratio (INR) monitoring and percent Time in Therapeutic INR Range (TTR) have impact on patient’s quality of life? Application of Beta regressions in a prospective 3 months setting. Value Health 2013;16:A535. Abstract.

Soini E, Hallinen T, et al. Cost-utility of first-line adalimumab and tocilizumab monotherapies in rheumatoid arthritis based on head-to-head data. Value Health 2013;16:A566. Abstract.

Soini E, et al. Level and factors impacting the patient dissatisfaction in the primary care visits based on the cross-section measurement – A prospective Finnish study. Value Health 2013;16:A336. Abstract.

Asseburg C, Riekkinen O, Karjalainen J, Kröger H, Soini E. Current and future strategy for osteoporosis screening and diagnostics: Cost-effectiveness of FRAX with or without pulse-echo ultrasound measurement of bone mineral density and DXA on demand. Value Health 2013;16:A564-5. Abstract.

Asseburg C, Valgarðsson S, Soini E. Cost-effectiveness of sequences of biologic treatments for moderate-to-severe psoriasis in Finland. Value Health 2013;16:A507-8. Abstract.

Martikainen J, et al. Early psychosocial intervention to delay institutionalization of patients with Alzheimer’s disease – a randomised controlled trial. 28th International Conference of Alzheimer’s Disease International, 18-20 April 2013, Taipei, Taiwan. Abstract booklet. Presentation.

Soini E, et al. Level and factors impacting the patient dissatisfaction in the primary care visits based on the cross-section measurement – A prospective Finnish study. 18th Nordic Congress of General Practice, Tampere, 22.8.2013. Conference paper.

Asseburg C, Soini E, et al. Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-TNF treatments in an outcomes-based risk-sharing scheme in Finland. Ann Rheum Dis 2013;72(Suppl3):434. Abstract.

Asseburg C, Riekkinen O, Karjalainen JP, Kröger H, Soini E. Cost-effectiveness of pulse-echo ultrasound measurement of bone mineral density as a tool for osteoporosis screening and diagnostics. European Congress on Osteoporosis and Osteoarthritis, Rome, Italy, 17-20 April 2013. Meeting website.

 

2012

Asseburg C, Soini E, et al. Cost-effectiveness and budget impact of certolizumab pegol against a mix of treatments in an outcomes-based risk-sharing scheme in Finland. Value Health 2012;15:A454. Abstract ebook.

Martikainen J, Soini E, et al. Economic impact of 13-valent pneumococcal conjugate vaccine (PCV13) in persons over 50 years of age with underlying chronic medical conditions in Finland. Value Health 2012;15:A388. Abstract ebook.

Issues in modeling the prognosis and treatment of non-communicable diseases using patient level simulation. Do the guidelines help us? Value Health 2012. Abstract, PDF.

Soini E, Mäkirinne-Kallio N, Martikainen J, Aarnio E, et al. Estimation of quality-adjusted survival with mild obstructive sleep apnoea and six quality of life (QoL) assessments: Comparison between trapezoid rule, cross-sectional and mixed model estimates. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:158. Abstract ebook.

Soini E, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis: Discrepancy between list cost prices and published costs. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:223. Abstract ebook.

Soini EJ, Martikainen JA, Mäkirinne-Kallio N, Aarnio E, et al. Comparison of EQ-5D- and 15D-based quality-adjusted life-years (QALY) in patients with mild obstructive sleep apnoea (MOSA) using mixed modelling: Measurement tool and preferences matter. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:159. Abstract ebook.

Asseburg C. Uncertainty in computer simulation models. Economics, Modelling and Diabetes: The Sixth Mt Hood Challenge. Baltimore, USA, 7-8 June 2012.

Hallinen T, Soini E, et al. Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland. Annals of the Rheumatic Diseases 2012;71(Suppl3):258. Poster presented at the Annual European Congress of Rheumatology (EULAR) 2012, Berlin. Open access.

Asseburg C. Estimating Weibull parameters from Kaplan-Meier curves. ISBA 2012, Kyoto. Abstract.

Hallinen T, Linnosmaa I, Tuovinen M, Soini E. Vaihtoehtoiskustannukset ja kustannusvaikuttavuus tuotantoteknologian muuttuessa: esimerkkinä eteisvärinän antikoagulaatiohoito. In: Klavus J (ed.) Terveystaloustiede 2012. Helsinki: THL, 69-73. Website.

 

2011

Soini E, Martikainen J, et al. Sequential treatment of follicular non-Hodgkin lymphoma: Cost-effectiveness and value of information. Value Health 2011;14:A239-240. Podium at the Annual ISPOR European Congress. PDF.

Hallinen T, Soini E, et al. Differential use of extended and instant release quetiapine: A naturalistic study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. Value Health 2011;14:A299. Abstract.

Theidel U, et al. Cost effectiveness of ticagrelor in the treatment of acute coronary syndrome in Germany. Annual ISPOR European Congress 2011. Abstract.

Willis M, et al. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). iHEA 2011. Podium.

Willis M, et al. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association (ADA) meeting 2011. Podium.

Soini E, Martikainen J, et al. Cost-effectiveness of first-line rituximab maintenance treatment for follicular lymphoma. Haematologica 2011;96(s2):402. Poster at the Annual Congress of European Hematology Association (EHA 2011). Abstract book.

 

2010

Soini E, Hallinen T, et al. Comprehensive health economic assessment of sequenced treatment with biologics in moderate-to-severe rheumatoid arthritis: Analysis based on ACR50 and ACR70 responses. Arthritis & Rheumatism 2010;62 Suppl 10:759. Poster at the Annual Scientific Meeting of American College of Rheumatology (ACR/ARHP 2010). ACR Notable Poster Nomination. Abstract.

Asseburg C. Model uncertainty in cost-effectiveness analysis. Combining Epidemiology & Economics for Measurement of Cancer Costs. Villa Mondragone, Italy, September 23, 2010. Podium. PDF.

Soini E, Hallinen T, et al. Cost-utility and multinomial expected value of perfect information of sequenced treatment with biologics in moderate-to-severe rheumatoid arthritis: Analysis based on clinically meaningful responses. Value Health 2010;13:A310. Abstract, PDF.

Cummins E, et al. Cost-effectiveness of golimumab in psoriatic arthritis from the UK payer perspective. Value Health 2010;13:A308. Abstract.

Hallinen T, Soini E. The impact of Finnish pharmaceutical pricing scheme in cost-effectiveness analyses. Value Health 2010;13:A249. Podium at the Annual ISPOR European Congress. Abstract, PDF.

Soini E, Hallinen T, et al. Cost-effectiveness, value of information and budget impact of certolizumab pegol compared to subcutaneous tumor necrosis factor (TNF) inhibitors and methotrexate in the treatment of moderate-to-severe rheumatoid arthritis in Finland. Value Health 2010;13:A243. Podium at the Annual ISPOR European Congress. Abstract.

Willis M, et al. The economic impact of weight loss for patients with newly diagnosed type 2 diabetes mellitus (T2DM) in the US. Value Health 2010;13:A59. AbstractPDF.

There is no single value of a QALY – context matters – in terms of the level of decision making! ISPOR Prague 7th November 2010; Issue Panel 3. Value Health 2010;13. PDF.

Soini E, Martikainen J, et al. Economic evaluation of lacosamide in the treatment of partial-onset epilepsy in Finland: Cost-effectiveness and budget impact modelling. ECHE 2010.

Ryynänen OP, Laitinen T, Soini E, et al. Bayesian methods for predicting treatment results. ECHE 2010. Podium.

Soini E, Hallinen T. Health economic study using survey data and modelling: Agomelatine, generic venlafaxine and placebo in the treatment of major depressive disorder. European Conference on Health Economics (ECHE) 2010.

Asseburg C, Ramsberg J, Peura P, Henriksson M, Purmonen T, Turunen J, Martikainen J. A Bayesian assessment of decision uncertainty in the choice between triptans for the treatment of migraine in Finland. International Society for Bayesian Analysis (ISBA) 2010 World Meeting on Bayesian Statistics. Meeting website.

Peura P, Purmonen T, Turunen J, Martikainen J. Tulosmuuttujan määrittämiseen liittyvä malliepävarmuus kustannusvaikuttavuusanalyyseissä. Podium. In: Klavus J (ed.) Terveystaloustiede 2010. Helsinki: THL, 74–7.

 

2009

He J, et al. Simulation of the Chinese Diabetes Treatment Guideline using the IHE/JNJ Diabetes Cost-Effectiveness Model. International Health Economics Association (iHEA) meeting 2009.

Hallinen T, Soini E, et al. Cost-utility analysis of different treatment strategies after the failure of first biologic treatment in rheumatoid arthritis (RA) in the Finnish setting. Value Health 2009;12:A432. Abstract,  PDF.

Peura P, Purmonen T, Martikainen J, et al. Critical review of published cost-effectiveness analyses of oral Triptans in the management acute migraine: different measures of efficacy extracted from the same meta-analysis. Value Health 2009;12:A387. Abstract.

Soini E, Martikainen J, et al. Cost-effectiveness and budget impact modelling of lacosamide in the treatment of partial-onset seizures in Finland. Value Health 2009;12:A367. Abstract, PDF.

Soini E, Hallinen T. Cost-utility of agomelatine, venlafaxine and placebo in the treatment of major depressive disorder (MDD) in Finland – Economic modelling study using representative population data. Award finalist. Value Health 2009;12:A359. Abstract, PDF.

Soini E, Stevenson M, Martikainen J, et al. Cost-utility of bosentan in the first-line treatment of pulmonary arterial hypertension in Finland – A discrete event simulation modelling. Value Health 2009;12:A335. Award finalist. Abstract, PDF.

Soini E, et al. Economic evaluation of trabectedin in the treatment of metastatic soft-tissue sarcoma (mSTS) in the Finnish setting. Value Health 2009;12:A277. Abstract, PDF.

Koskela T, Ryynänen OP, Soini E. Predicting persistent frequent use of the primary health care services in a Finnish setting: a Bayesian approach. Value Health 2009;12:A237. Award finalist. Abstract, PDF.

Laine J, Soini E, Martikainen J. The role of economic evaluation in the health technology assessment (HTA) of vaccines – Lessons learned from Finland. Value Health 2009;12. Abstract, PDF.

Willis M, et al. The impact of adherence on the costs and benefits of intensive lifestyle management (ILM) in overweight and obese patients at high risk for type-2 diabetes mellitus (T2DM). Value Health 2009;12:A132. Abstract, PDF.

Asseburg C, et al. Validation of the IHE/J&J economic simulation model of type-2 diabetes mellitus (T2DM). Value Health 2009;12:A26. Abstract, PDF.

Soini E. Lääkehoitojen terveystaloudellinen arviointi. Harvinaiset Sairaudet -päivä 9.10.2009. Podium.

Koskela T, Ryynanen OP, Soini E. Perusterveydenhuollon vastaanottotoiminnan eri tuottamismallien kustannus-vaikuttavuusanalyysi. SYLY Päivät 2009 Yleislääketieteen päivät 8-9.10.2009 Tieteestä toiminnaksi. Podium.

Koskela T, Ryynänen O, Soini E. Risk factors for Persistent Use of the Primary Health Care Services: A Bayesian approach. 15th Wonca Europe Congress 16-19 September 2009. Abstract book (PDF).

Soini E, Martikainen J, et al. Cost-effectiveness and budget impact modelling of lacosamide in the treatment of partial-onset epilepsy in Finland. IV Neurologiapäivät Neuroscience Finland 2009; P-11.

Purmonen T, Peura P, Turunen J, Martikainen J. Cost-effectiveness of oral triptan therapy in Finland. 4th Nordic Social Pharmacy and Health Services Research Conference June 15-16, 2009, 13.

 

2008

Soini E, et al. What is politician’s and clinician’s willingness to pay (WTP) for future health benefit based on 15D, EQ-5D and life-years? A contingent valuation (CV) among 8 diseases with the total of 1092 cases. Value Health 2008;11:A566. Podium at the Annual ISPOR European Congress. Abstract.

Soini E, Martikainen J, et al. Economic evaluation of cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regime with or without Rituximab (R) in the 2nd line treatment of follicular non-hodgin lymphoma. Value Health 2008;11:A470. Abstract, PDF.

Purmonen T, Auvinen P, Martikainen J. Budget impact analysis of different treatment protocols for trastuzumab. Value Health 2008;11:A462. Abstract, PDF.

Tamminen K, Laine J, Soini E, Martikainen J, et al. Cost-effectiveness analysis of symbicort SMART® versus fixed combination treatments in Finland. Value Health 2008;11:A449. Abstract.

Martikainen J, Soini E, et al. Searching the optimal treatment mix strategy with a treatment mix chart approach – The case of cholesterol lowering in Sweden. Value Health 2008;11:A417. Abstract.

Lusa T, Soini E, Martikainen J, et al. Zoledronic Acid 5 mg once yearly is an efficient and potentially cost-effective treatment option for the management of postmenopausal osteoporosis in Finland – A discrete event simulation modelling. Osteoporosis International 2008;19:S71.

Peura P, Martikainen J, Hallinen T, Soini E, et al. Statiinien kustannusvaikuttavuus sepelvaltimotautitapahtumien ehkäisyssä. Podium. In: Klavus J (ed.) Terveystaloustiede 2008. Helsinki: STAKES, 30–3. PDF.

Koskela T, Ryynänen OP, Soini E. Terveyspalvelujen pitkäaikaisen suurkäyttäjän ennustetekijät. Valtakunnalliset Lääkäripäivät – Luentolyhennelmät 2008.

 

2007

Blomstedt P*, Soini E*, et al. Empirical Evaluation of the Predictive Performance of Classification Tools in Coronary Heart Disease – P-Course, a Naive Bayes Tool, Outperforms Novel Logistic Regression Approaches. Value Health 2007;10:A428. *Equal contribution. Abstract, PDF.

Soini E. Multinomial Propensity Score Estimators and Multivariate Explanatory Techniques in a Real-Life Acute Coronary Heart Dsease Study – The QALYs and Costs of Medication, PTCA and CABG Treatment Modality Are Highly Dependent on the Methods Used. Value Health 2007;10:A427. Abstract, PDF.

Peura P, Martikainen JA, Hallinen T, Soini E, et al. Cost-Effectiveness of Atorvastatin, Rosuvastatin, and Simvastatin in Reducing LDL-Cholesterol to Meet the European Target Level – Bayesian Meta-Analysis and Simulation. Value Health 2007;10:A416-7. Abstract, PDF.

Purmonen T*, Martikainen J*, Soini E, et al. Sunitinib Malate Provides Additional Survival and Value for Money as a Second Line Treatment for Metastatic Renal Cell Carcinoma (mRCC) – An Economic Evaluation Using Bayesian Approach. Value Health 2007;10:A337. *Equal contribution. Abstract, PDF.

Hallinen T, Karjalainen J, Hahl J, Torvinen S, Martikainen J. Reduction in Total Treatment Costs through Improved Pharmaceutical Treatment of Obstructive Airway Diseases. Value Health 2007;10:A308. Award finalist. Abstract, PDF.

Soini E. Positive Investment Interval (PII) and Payback Period (PP) Offer Different Interpretations in Health Technology Investment Decisions: PII Is a Matter of Being and PP Is a Matter of Turning Beneficial – A Case of Hemophilia A. Value Health 2007;10:A284. Abstract, PDF.

Soini E, Hallinen T, et al. Advate Is Cost-Effective Investment in Hemophilia A Treatment when Pathogens Emerge – A Scenario-Based Economic Evaluation and Positive Investment Interval (PII) Evaluation. Value Health 2007;10:A281. Abstract, PDF.

Niskanen L, Peura P, Hallinen T, Soini E, Martikainen J. The cost-effectiveness of atorvastatin, rosuvastatin and simvastatin in treating patients to LDL-cholesterol targets. European Heart Journal 2007;28:S860. Meeting website.

Soini E, et al. Leikkaukseen kotoa (LEIKO) -toimintamalli tuottaa enemmän elämänlaatua, vähentää infektioita ja säästää euroja. Valtakunnalliset Lääkäripäivät – Luentolyhennelmät 2007, 273.

Purmonen T, Martikainen J, Soini E, et al. Sytokiinihoidon läpikäyneiden munuaissyöpäpotilaiden (mRCC) hoito Suomessa. Valtakunnalliset Lääkäripäivät – Luentolyhennelmät 2007, 261.

Soini E, et al. Leikkaukseen kotoa (LEIKO) -toimintamalli on hyödyllinen – Tapahtumaperusteinen kustannus-utiliteetti-, kustannus-vaikuttavuus- ja riski-hyötyanalyysi. Podium. In: Klavus J (ed.) Terveystaloustiede 2007. Helsinki: STAKES, 36–42. PDF.

Martikainen J. Iteratiivinen lähestymistapa lääkkeiden ja muiden terveydenhuollon menetelmien arviointiin. Podium. In: Klavus J (ed.) Terveystaloustiede 2007. Helsinki: Stakes Työpapereita 2007;(2):62–6. Podium. PDF.

 

2006

Martikainen J, et al. Cost-Effectiveness of Life-Style Intervention for Hypertension: An Open Randomised Controlled Trial. Value Health 2006;9:A340. Abstract.

Soini E, et al. Economic Evaluation Comparing From Home To Operation and Conventional Process of Laparoscopic Cholecystectomy: Prospective Randomized Controlled Trial. Value Health 2006;9:A331. Award finalist. Abstract, PDF.

Soini E, et al. Predicting Violent Offending among Mentally Ill in a Multinational Setting – Naive Bayesian Fusion and Model Merging with P-Course. Value Health 2006;9:A316-7. Podium at the Annual ISPOR European Congress. Award finalist and award winner. Abstract, PDF.

Turunen J* & Soini E*. Presenting Ignorance: A Possibility Interval Approach to Depict High-Level Uncertainty Due to Censoring or Non-Respondents. Value Health 2006;9:A271. *Equal contribution. Award finalist. Abstract, PDF.

Soini E, Martikainen J, et al. Efficient Data Mining and Probabilistic Inference with P-Course: A Bayesian Method with Multilevel Priors for Medical Applications. Value Health 2006;9:A270. Abstract, PDF.

Soini E, et al. 15Ds – A New Dynamic Quality of Life Tool with Increased Sensitivity and Improved Composite Structure for Recall Bias and Response Sift Adjustments. Value in Health 2006;9(6):A194. Podium at the Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress. Abstract, PDF.

Soini E, et al. Bayesian forecasting models in psychiatry: Predicting violent behaviour in forensic psychiatric patients. Statistical Methods in Psychiatric Research, 2006. Tampere: the 28th Nordic Congress of Psychiatry. Podium.

Soini E, et al. P-Course in action. Statistical Methods for Health Care Data Analysis, 2006. Podium.

Ryynänen O, Soini E. Forecasting cost-effectiveness of health care by a naive Bayes classifier. Statistical Methods for Health Care Data Analysis, 2006. Podium.

Linnosmaa I, Karjalainen S, Martikainen J, et al. Yksilö- ja ryhmähoidon kustannusvaikuttavuus lasten lihavuuden hoidossa. Podium. In: Klavus J (ed.) Terveystaloustiede 2006. Helsinki: STAKES, 50–3. PDF.


Muut julkaisut 2006-

Other publications 2006-

 

2017

Mikä on tekemättömän työn hinta? Selvitys pitkäaikaissairauksien vuoksi tekemättä jäävän työn kustannuksista. Presenter: specialist clinician Jan Schugk. SuomiAreenan Kestävän Terveydenhuollon Aamiainen ”Tekemätöntä työtä, näkymättömiä kustannuksia” 12.7.2017 [forthcoming]. ESiOR team: E. Soini, M. Karjalainen, S. Tiilikainen, P. Mankinen, S. Väätäinen, J. Martikainen, T. Hallinen. Contact: Erkki Soini.

Psoriaasi (iho ja nivelet) (online). Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 2017 (viitattu 2.5.2017). Saatavilla internetissä: http://www.kaypahoito.fi/. Asiantuntija: Soini E.

Soini E. Käypä hoito -suositus: Psoriaasi (iho ja nivelet), Lisätietoa aiheesta, [nix02465]=Biologisten lääkkeiden kustannusvaikuttavuus nivelpsoriaasin hoidossa. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 3.3.2017 (viitattu 2.5.2017). Verkkosivu: http://www.terveysportti.fi/xmedia/nix/nix02465liitteet.pdf

Soini E. Biologisten lääkkeiden kustannusvaikuttavuus nivelpsoriaasin hoidossa. Suomalaisen Lääkäriseuran Duodecimin ja Suomen Ihotautilääkäriyhdistyksen asettama työryhmä. Helsinki: Suomalainen Lääkäriseura Duodecim, 1.3.2017 (viitattu 2.5.2017). Saatavilla: http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=nix02465&suositusid=hoi50062

Hallinen T, Soini E. Apiksabaanin kustannusvaikuttavuus eteisvärinäpotilailla. BestPractice Diabetes ja Sydänsairaudet 2017;(3):12-5. https://bestprac.fi/2017/03/22/apiksabaanin-kustannusvaikuttavuus-eteisvarinapotilailla/

 

2016

ESiOR Oy. From Data to Competitive Advantage. In: Nordic conference on Real World Data – Collaboration between pharma industry and Academia, 30.11.2016, Helsinki. Presenter: Soini E. Available http://www.pif.fi/sites/default/files/attachments/esior.pdf

Sotessakin perustellaan hankintoja tiedolla. Terveydenhuollossa tapahtuu. Terveys & Talous -lehti 2016;(5):24. Haastateltu: Soini E. Juttu http://mediasepat.fi/Tt052016/#/article/24/page/1-1

Soini E. Kroonisen lymfaattisen leukemian hoidon kustannusvaikuttavuus Suomessa ja sen uudet tulkinnat: Kliininen kustannushyöty ja vaikuttavuusinvestoiminen. BestPractice ONKOLOGIA / HEMATOLOGIA 2016;5(18):30-2. Journal page

Soini E. Eteisvärinän antikoagulaatiohoito muutoksen myllerryksessä: Muuttuvatko kokonaiskustannus ja vaikuttavuus maksajan mukana? Diagnostisen laboratoriotoiminnan kustannukset ja vaikuttavuus. Terveys- ja talouspäivät, 15.9.2016, Kuopio. Meeting website.

Soini E. Expert Solutions in Outcomes Research. Asiantuntijaratkaisuja vaikuttavuustutkimukseen. Lakityöryhmän WorkShop, SoTe-tiedon toissijainen käyttö: ”Tiedolla johtaminen, ohjaus ja valvonta”. 16.2.2016, Meritullinkatu 8, STM. Esitys.

Paneelikeskustelu: Yritykset terveystiedon äärellä. SoTe-tiedot hyötykäyttöön seminaari. STM: 27.1.2016. Mukana: Soini E.

Aarnio E, Martikainen J. Lääkehoitoon sitoutumisella on merkittäviä yhteiskunnallisia vaikutuksia. sic! 2016.

 

2015

Martikainen J, Viramo P. Muistisairaudet ja terveystalous. In: Muistisairaudet. 2. uudistettu painos, p. 44–55. Eds. Erkinjuntti T, Remes A, Rinne J, Soininen H. Duodecim: Helsinki, 2015. Organisation’s website.

Soini E. Terveystalousanalyysien hyödyntäminen ja käyttö asiakasviestinnässä. Lääketietokeskus: Terveystalousanalyysit ja tilastolliset päättelyt tutuiksi – miten hyödynnän malleja ja tuloksia omassa työssäni. Helsinki: koulutus 16.9.2015. Organisation’s website.

 

2014

Terveydenhuollon rahoituspäätökset – Millä perusteilla ne tehdään, mikä on kustannusvaikuttavuustiedon merkitys? KWRC Seminar 11.9.2014. Puheenjohtaja: Soini E.

Laskentamalli apuna tilojen hahmottamisessa. Haastateltu: Soini E. Terveys ja talous 2014;77(2):44. Uutinen.

 

2013

Soini E. Kustannusvaikuttavuus pienillä potilasryhmillä. Lääketietokeskus: Vaikuttavuusiltapäivä – kohti räätälöityjä lääkehoitoja. Helsinki: koulutus 10.10.2013. Organisation’s website.

Seminaari tuotannon menetysten arvottamisesta. KWRC Seminar 27.5.2013. Puheenjohtaja: Martikainen J.

Soini E. Productivity costs in Finnish cost-effectiveness assessments. KWRC seminar 27.5.2013.

Soini E. Reuman hoidon kustannusvaikuttavuus Suomessa. BestPractice Reumasairaudet – Lääketieteen asiantuntijoiden ammattilehti 2013;1(3):7-9. Journal website.

Mäkirinne-Kallio, N. VLCD-dieetin ja aktiivisen elämäntapaohjauksen kustannusvaikuttavuus lievän ja keskivaikean obstruktiivisen uniapnean hoidossa. University of Eastern Finland, 2013. Master’s Thesis made for ESiOR Oy. Supervisor: Erkki Soini.

Kosunen, M. Sairaanhoitopiirien palveluiden hinnoittelu – onkologisten lääkkeiden antokustannukset somaattisen erikoissairaanhoidon avohoidossa. University of Eastern Finland, 2013. Master’s Thesis made for ESiOR Oy. Supervisor: Erkki Soini.

Soini E. Terveystaloustiede osaksi terveydenhuollon suunnittelua ja päätöksentekoa. KunnallisSuomi 2013;(1):39. Organisation’s website.

Asseburg C (ed). Economics, modelling and diabetes – The Mt. Hood Newsletter. ESiOR Oy, Kuopio, Finland. Website.

 

2012

Soini E. Kustannusvaikuttavuustiedon tuottamisen rooli, haasteet ja mahdollisuudet nyt ja tulevaisuudessa. KWRC Seminar 22.10.2012.

Soini E. Follikulaarisen lymfooman sekventiaalisen hoidon kustannusvaikuttavuus. BESTPRACTICE ONKOLOGIA / HEMATOLOGIA Lääketieteen asiantuntijoiden ammattilehti 2012;1(2):28-31. Organisation’s website.

Ainutlaatuinen kokonaisuus – Lääketutkimuksen kehittäjät. In: Lääketeollisuus ry:n ilmoitusliite Kauppalehti 21.11.2012, Tulevaisuuden lääkkeet, p. 3. Yksi haastatelluista: Soini, E.

Fimean suositus lääkkeiden hoidollisen ja taloudellisen arvon arvioinnista (Fimea recommendation for the assessment of the therapeutic and economic value of pharmaceuticals). Fimea kehittää, arvioi ja informoi -julkaisusarja 2/2012 (Serial Publication Fimea Develops, Assesses and Informs 2/2012). Projektiryhmän jäsen / project team member: Martikainen, J. PDF.

Rasvan laadun muutoksen ja suolan vähentämisen taloudellinen merkitys. Tie Sydämeen 2012;(1):4-5. Lähteenä luento 7.3.2012: Martikainen J. Link.

Soini E. ESiOR auttaa toiminnan kriittisessä tarkastelussa. Kunnallissuomi 2012;(1):22. Organisation’s website.

Asseburg C (ed). Economics, modelling and diabetes – The Mt. Hood Newsletter. ESiOR Oy, Kuopio, Finland. Website.

 

2011

Soini E. Terveystaloustrendiksi todellisen hoitotilanteen kustannusvaikuttavuus. Impulssi 2011;3:16-7.

Soini E. Myytkö lisäkustannuksia vai kustannusvaikuttavuutta? Podium 2011;5:19.

Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2011;syksy. Suomen Lääkärilehden välissä julkaistu tiedotuslehtinen. Haastateltu: Soini, E.

Martikainen J, Asseburg C, et al. Triptaanien kustannusvaikuttavuus akuutin migreenikohtauksen hoidossa. Lääkealan turvallisuus- ja kehittämiskeskus Fimea. Fimea kehittää, arvioi ja informoi –julkaisusarja 1/2011. Open access.

GAO. Value in Health Care. Key Information for Policymakers to Assess Efforts to Improve Quality While Reducing Costs. Washington: United States Government Accountability Office’s Report to Congressional Requesters, 2011. One of the responders: Soini, E. PDF.

Soini E. Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa? Harvinaiset Sairaudet -lehti 2011;1:26-31.

Peura P, Turunen J, Purmonen T, Happonen P, Martikainen J. Mitä lääkehoitojen kustannusvaikuttavuus tarkoittaa? Sic! 2/2011. Journal website.

 

Eksoten palvelut ovat asiakastyytyväisyyskyselyn perusteella keskitasoa. 11.3.2011.

 

2010

Soini E. Cost-effectiveness of modern anticoagulation treatment. Session: Who benefits from modern anticoagulation treatment – Practical guidelines. Kardiologian päivät 14.10.2010.

Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2010; syksy:4. Haastateltu: Soini, E.

Soini E. Trabektediinin kustannusvaikuttavuus edenneen pehmytkudossarkooman hoidossa. Harvinaiset sairaudet -päivä 29.10.2010, Finlandia-talo, Helsinki. Podium.

Soini E. ESiOR laittaa numerot puhumaan. KunnallisSuomi 2010;(10):8. Organisation’s website.

Erntoft S, Asseburg C, et al. Vilken betydelse har hälsoekonomi vid prioriteringar? – Ett experiment bland beslutsfattare och en analys av faktiska  prioriteringar. Linköping, Prioriteringscentrum 2010:3.

Martikainen J. Lääkehoitojen taloudellisen arvon arvioinnin perusperiaatteet. Onko lääke hintansa väärti? Lääkepäivät 19.-20.3.2010, 78-79. Toim. Pirinen O, Aducate Reports and Books 1/2010, Itä-Suomen yliopisto, Koulutus- ja kehittämispalvelu Aducate, Kuopio 2010. Podium. PDF.

Asseburg C. Experiences from The United Kingdom and Sweden in conducting pharmacoeconomic studies. Onko lääke hintansa väärti? Lääkepäivät 19.-20.3.2010, 80-81.Toim. Pirinen O, Aducate Reports and Books 1/2010, Itä-Suomen yliopisto, Koulutus- ja kehittämispalvelu Aducate, Kuopio 2010. Podium. PDF.

 

2009

Soini E. Terveystaloudellinen arviointi tutkimusten yhteydessä. Lääketietokeskus: Työkaluja lääkkeiden taloudelliseen arviointiin. Helsinki: koulutus 25.11.2009. Organisation’s website.

Soini E. Astman hoito – kuluja vai säästöjä? Helsingin Aluelääkäriyhdistyksen syyskokous 25.9.2009.

Soini E. Kustannus-vaikuttavuustieto: miten sitä voidaan hyödyntää ja miten sitä on hyödynnetty lääketeollisuudessa, sairaaloissa ja elintarvikealan yrityksissä. KWRC Seminar 8.5.2009.

Soini E. Lääkehoitojen terveystaloudellinen arviointi. Harvinaiset sairaudet ja harvinaissairauslääkkeet kansallisella tasolla. Harvinaiset Sairaudet -päivä 9.10.2009. DVD.

Soini E. Harvinaissairauslääkkeistä ja niiden taloudellisesta arvioinnista. Mediuutiset 30.3.2009.

Pänkäläinen E. Trastutsumabin kustannusvaikuttavuus varhaisen vaiheen HER2-positiivisen rintasyövän hoidossa. Cost-effectiveness of trastuzumab in early HER2-positive breast cancer. Kuopion yliopisto 2009.

 

2008

Soini E. Follikulaarisen lymfooman 2. linjan hoidon kustannusvaikuttavuus: Käypä Hoito -suosituksen mukaisten hoitostrategioiden arviointi. KWRC Seminar 1.10.2008.

Soini E. Money for Value? – Paljonko käyttöönotto maksaa? SRY syyskokous 17.9.2008.

Soini E. Terveysteknologian arvo ja budjettivaikutukset syytä selvittää. KunnallisSuomi 2008;(12):3.

Martikainen J. Terveystaloudellinen tutkimus osana hoitomenetelmien hoidollisen ja taloudellisen arvon arviointia. Therapia 2008;(3):14-7.

Purmonen T, Martikainen J. Talouspäällikön uusi työväline. Impakti 2008;11:4-5.

Martikainen J. Uusia työkaluja hoitomenetelmien arviointiin. Terveys ja talous 2008;(5-6):72-3.

Martikainen J. Terveystaloudellinen näkökulma muistisairauksiin. Muisti 2008;21:26-7.

Soini E. Ominaisuusvakiointi valikoitumisharhan hallinnassa – Kohteena ei-kokeelliseen asetelmaan perustuva terveystaloudellinen arviointitutkimus. Propensity Score Adjustment for Selection Bias Control – The Problematic Subject of Non-experimental Setting in Health Economic Evaluations. Kuopion Yliopisto 2008. PDF.

Martikainen J. Application of Decision-Analytic Modelling in Health Economic Evaluations. Päätösanalyyttisten menetelmien soveltaminen terveystaloudellisessa arviointitutkimuksessa. Kuopion Yliopisto 2008;E 152. AbstractPDF.

 

2007

Peura P, Niskanen L, Martikainen J. Kuinka arvioida lääkehoidon vaikuttavuutta suhteessa sen aiheuttamiin kustannuksiin? Esimerkkinä kolesterolin lääkehoito. Therapia 2007;(4):56-9.

Soini E, et al. LEIKO – leikkaukseen kotoa: prosessi terveystaloustieteellisestä näkökulmasta. Pinsetti 2007;(2):26-8.

Soini EJO, Martikainen JA, et al. Sepelvaltimopotilaan konservatiivisen, pallolaajennus- ja ohitusleikkaushoidon kustannukset, vaikuttavuus, kustannusvaikuttavuus ja Bayes-ennustemallinnus. Acute coronary syndrome: cost-effectiveness and Bayesian predictive models of conservative treatment, CABG and PTCA. Julkaisussa: Akuutin sydänpotilaan hoitoketjun arvioinnin kaksi näkökulmaa, 83-157. 2007. Kuopion yliopisto E 141.

 

2006

Miten päätökset onnistuvat epävarmuudessa? Bayes menetelmiä testataan myös terveydenhuollossa. Impakti 2006;(4):16-7. Haastateltu: Soini E, Martikainen J.

Martikainen J, et al. Hoidon kustannukset ja elämänlaadulliset menetykset. Julkaisussa: Kliininen neuroimmunologia, 184-7. 2006.

Soini E. Bayesilainen tilastotiede päätösprosessin analysoinnin apuvälineenä – Esimerkkinä prosessin lisäarvon ennakoinnin laatufunktio. Bayesian statistics, a tool for decision analysis – An example of quality function as the predictor of procedural added value. Kuopion yliopisto. 2006.

Linnosmaa I, Hermans R, Hallinen T. Price-cost margin in the pharmaceutical industry. Empirical evidence from Finland. Julkaisussa: Sustainable Biotechnology Development – New Insights into Finland. ETLA 2006; B217: Appendix 2. Journal website.